Osimertinib, a third-generation EGFR-TKI, that targets activating mutations (EGFRm) and resistance mutations (T790M), has demonstrated robust systemic activity and a better CNS penetration with sustained tumor regression of BM. Here, EGFR is linked to neoplasm.